Your browser doesn't support javascript.
Safety of coronavirus disease 2019 vaccines in 213 adult patients with sickle cell disease.
Joseph, Laure; Corbasson, Anne; Manceau, Sandra; Khimoud, Djamal; Meunier, Benoit; Cheminet, Geoffrey; Lefrere, François; Jannot, Anne-Sophie; Lu, Estelle; Arlet, Jean-Benoît.
  • Joseph L; Department of Biotherapy, French National Sickle Cell Disease Referral Center, Hôpital Necker, Assistance-Publique Hôpitaux de Paris, Paris, France.
  • Corbasson A; Laboratoire d'excellence sur le globule rouge GR-ex, Paris, France.
  • Manceau S; Internal Medicine Department, French National Sickle Cell Disease Referral Center, Hôpital Européen Georges Pompidou, Assistance-Publique Hôpitaux de Paris, Paris, France.
  • Khimoud D; Department of Biotherapy, French National Sickle Cell Disease Referral Center, Hôpital Necker, Assistance-Publique Hôpitaux de Paris, Paris, France.
  • Meunier B; Laboratoire d'excellence sur le globule rouge GR-ex, Paris, France.
  • Cheminet G; Internal Medicine Department, French National Sickle Cell Disease Referral Center, Hôpital Européen Georges Pompidou, Assistance-Publique Hôpitaux de Paris, Paris, France.
  • Lefrere F; Department of Biotherapy, French National Sickle Cell Disease Referral Center, Hôpital Necker, Assistance-Publique Hôpitaux de Paris, Paris, France.
  • Jannot AS; Internal Medicine Department, French National Sickle Cell Disease Referral Center, Hôpital Européen Georges Pompidou, Assistance-Publique Hôpitaux de Paris, Paris, France.
  • Lu E; Faculty of Medicine, Université de Paris Cité, Paris, France.
  • Arlet JB; Department of Biotherapy, French National Sickle Cell Disease Referral Center, Hôpital Necker, Assistance-Publique Hôpitaux de Paris, Paris, France.
Br J Haematol ; 2022 Nov 10.
Article in English | MEDLINE | ID: covidwho-2264975
ABSTRACT
Given the lack of information about safety of the COVID-19 vaccines for sickle cell disease (SCD) patients, we sought to determine whether COVID-19 vaccine was associated with subsequent hospital admission for vaso-occlusive events (VOEs). We included 402 patients with SCD, including 88 regularly transfused. As of July 31, 2021, 213 (53.0%) of them had received a least one dose of COVID vaccine (Pfizer 93.0%). We showed similar risk of hospital admission for a VOE among vaccinated patients (whether transfused or not) and among a control group of non-vaccinated patients matched for age, sex and genotype.
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Prognostic study Topics: Vaccines Language: English Year: 2022 Document Type: Article Affiliation country: Bjh.18547

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Prognostic study Topics: Vaccines Language: English Year: 2022 Document Type: Article Affiliation country: Bjh.18547